Patents by Inventor Alex Cortez

Alex Cortez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DC-SIGN ANTIBODY DRUG CONJUGATES
    Publication number: 20230053449
    Abstract: Provided herein are antibodies to DC-SIGN, conjugates of DC-SiGN antibodies, and DC-SiGN antibody fusion proteins and the use of such antibodies, conjugates, and fusion proteins for the treatment of diseases such as cancer.
    Type: Application
    Filed: October 30, 2019
    Publication date: February 23, 2023
    Inventors: Lisa BARNETT, Steven BENDER, Alex Cortez, Sarah COX, Jonathan DEANE, Scott Martin GLASER, Ben WEN, Tom Yao-Hsiang WU
  • ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST
    Publication number: 20210346387
    Abstract: Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.
    Type: Application
    Filed: February 22, 2021
    Publication date: November 11, 2021
    Inventors: Alex CORTEZ, Bernhard Hubert GEIERSTANGER, Timothy Z. HOFFMAN, Shailaja KASIBHATLA, Tetsuo UNO, Xing WANG, Tom Yao-Hsiang WU
  • Antibody conjugates comprising toll-like receptor agonist
    Patent number: 10973826
    Abstract: Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: April 13, 2021
    Assignee: Novartis AG
    Inventors: Alex Cortez, Bernhard Hubert Geierstanger, Timothy Z. Hoffman, Shailaja Kasibhatla, Tetsuo Uno, Xing Wang, Tom Yao-Hsiang Wu
  • Compounds and compositions as toll-like receptor 7 agonists
    Patent number: 10844068
    Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: November 24, 2020
    Assignee: Novartis AG
    Inventors: Alex Cortez, Timothy Hoffman, Yongkai Li, Tom Yao-Hsiang Wu, Xiaoyue Zhang
  • ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES
    Publication number: 20200164084
    Abstract: Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies. In some embodiments, the conjugates are used in combination with a second therapeutic agent.
    Type: Application
    Filed: April 27, 2018
    Publication date: May 28, 2020
    Inventors: Alex Cortez, Bernhard Hubert Geierstanger, Rodrigo Andreas Hess, Timothy Z. Hoffman, Shailaja Kasibhatla, Tetsuo Uno, Xing Wang, Tom Yao-Hsiang Wu
  • COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS
    Publication number: 20190345166
    Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.
    Type: Application
    Filed: July 24, 2019
    Publication date: November 14, 2019
    Inventors: Alex CORTEZ, Timothy HOFFMAN, Yongkai LI, Tom Yao-Hsiang WU, Xiaoyue ZHANG
  • Compounds and compositions as toll-like receptor 7 agonists
    Patent number: 10407431
    Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: September 10, 2019
    Assignee: Novartis AG
    Inventors: Alex Cortez, Timothy Hoffman, Yongkai Li, Tom Yao-Hsiang Wu, Xiaoyue Zhang
  • Adsorption of immunopotentiators to insoluble metal salts
    Patent number: 10098949
    Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: October 16, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Manmohan Singh, David A. G. Skibinksi, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
  • COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS
    Publication number: 20180186802
    Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.
    Type: Application
    Filed: February 27, 2018
    Publication date: July 5, 2018
    Inventors: Alex CORTEZ, Timothy HOFFMAN, Yongkai LI, Tom Yao-Hsiang WU, Xiaoyue ZHANG
  • Compounds and compositions as toll-like receptor 7 agonists
    Patent number: 9944649
    Abstract: The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: April 17, 2018
    Assignee: Novartis Ag
    Inventors: Alex Cortez, Timothy Hoffman, Yongkai Li, Tom Yao-Hsiang Wu, Xiaoyue Zhang
  • ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST
    Publication number: 20170121421
    Abstract: Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.
    Type: Application
    Filed: October 25, 2016
    Publication date: May 4, 2017
    Applicant: NOVARTIS AG
    Inventors: Alex CORTEZ, Bernhard Hubert GEIERSTANGER, Timothy Z. HOFFMAN, Shailaja KASIBHATLA, Tetsuo UNO, Xing WANG, Tom Yao-Hsiang WU
  • COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS
    Publication number: 20170044168
    Abstract: The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.
    Type: Application
    Filed: April 29, 2015
    Publication date: February 16, 2017
    Applicant: NOVARTIS AG
    Inventors: Alex CORTEZ, Timothy HOFFMAN, Yongkai LI, Tom Yao-Hsiang WU, Xiaoyue ZHANG
  • ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS
    Publication number: 20160213776
    Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
    Type: Application
    Filed: April 7, 2016
    Publication date: July 28, 2016
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Manmohan SINGH, David A.G. SKIBINKSI, Tom Yao-Hsiang WU, Yongkai LI, Alex CORTEZ, Xiaoyue ZHANG, Yefen ZOU, Timothy Z. HOFFMAN, Jianfeng PAN, Kathy YUE
  • Adsorption of immunopotentiators to insoluble metal salts
    Patent number: 9315530
    Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: April 19, 2016
    Assignee: Novartis AG
    Inventors: Manmohan Singh, David A. G. Skibinski, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
  • COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
    Publication number: 20150225432
    Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
    Type: Application
    Filed: April 24, 2015
    Publication date: August 13, 2015
    Applicant: Novartis AG
    Inventors: Alex Cortez, Yongkai Li, Manmohan Singh, David Skibinski, Kathy Yue, Tom Yao-Hsiang Wu, Xiaoyue Zhang
  • Compounds and compositions as TLR activity modulators
    Patent number: 9045470
    Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: June 2, 2015
    Assignee: IRM LLC
    Inventors: Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Kathy Yue, Xiaoyue Zhang, Manmohan Singh, David Skibinski
  • Compounds and compositions as TLR activity modulators
    Patent number: 8895577
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: November 25, 2014
    Inventors: Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Yefen Zou, Pranab Mishra, Xiaoyue Zhang, Nicholas Valiante
  • ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS
    Publication number: 20130274465
    Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
    Type: Application
    Filed: September 1, 2011
    Publication date: October 17, 2013
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Manmohan Singh, David A.G. Skibinski, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
  • COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
    Publication number: 20130253002
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Application
    Filed: April 22, 2013
    Publication date: September 26, 2013
    Inventors: TOM YAO-HSIANG WU, YONGKAI LI, ALEX CORTEZ, YEFEN ZOU, PRANAB MISHRA, XIAOYUE ZHANG, NICHOLAS VALIANTE
  • Compounds and compositions as TLR activity modulators
    Patent number: 8466167
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: June 18, 2013
    Assignees: IRM LLC, Novartis AG
    Inventors: Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Yefen Zou, Pranab Mishra, Xiaoyue Zhang, David Skibinski, Manmohan Singh, Nicholas Valiante